Pantherna Therapeutics is seeking for diverse types of collaborations with pharmaceutical and biotech companies.

• The Company plans to partner its in-house development programs at the pre-clinical or clinical stage.
• One of Pantherna’s programs focuses on patients with an Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition associated with viral and bacterial lung infections.
• In addition, Pantherna is interested in research collaborations and pre-clinical development agreements with industry partners to extend the applications of Pantherna’s proprietary lipid nanoparticle mRNA expression technology platforms (PTX_LNP®, PTXmRNA®).
• Pantherna is open to research agreements with academia and biotech that have complementary research interest and corresponding capabilities in selected indications proposed by the respective partner.

Business Development Contact

• Individuals or organizations interested in exploring potential collaboration opportunities are invited to contact:
  Dr. Klaus Giese, CEO
  k.giese@pantherna-therapeutics.com